Dr. Roger McIntyre Elected Board Chair of Champignon Brands Inc.

 Dr. Roger McIntyre has been elected Chairman of the Board of Directors of Champignon Brands Inc. (" Champignon " or the " Company ") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF).

A foremost international expert in depression and suicide, Dr. McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto , heads the Mood Disorders Unit at the University Health Network in Toronto and has appointments among scientific and clinical organizations across the US and Asia .

Dr. McIntyre was appointed to the Board of Directors of Champignon on July 22, 2020 and assumed the role of CEO on May 11 , 2020.  He has set out a strategic direction for the business which includes a focus on "breakthrough treatments of depression" through the development of government-approved ketamine compounds and a network of treatment clinics. The Company's dual mission is to help those suffering from mental health disorders in its own ketamine-based clinics and to develop the next generation of novel psychedelic treatments and delivery systems.

The Company continues to work with the British Columbia Securities Commission to address the ongoing continuous disclosure review and is confident that the review will be resolved soon.

Bill Wilkerson , LL. D. (Hon), appointed to the Board of Directors of Champignon on May 22, 2020 , has been elected Vice-Chair of the Board, bringing to the position extensive experience in business, government, and mental health.

For more information on Champignon Brands Inc. please visit our website: https://champignonbrands.com .

The Canadian Securities Exchange and its Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements.  These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which are available at www.sedar.com .  There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.

SOURCE Champignon Brands Inc.

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Q4 Fiscal 2025 Highlights Revenue of $2.3 million, a 29.0% increase over Q3 2025 Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End On April 18, 2026, President Donald Trump signed an... Keep Reading...
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain

On April 18, US President Donald Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments for Serious Mental Illness, an executive order (EO) to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...

Interactive Chart

Latest Press Releases

Related News